87679 20200716101420.0 doi 10.1093/jac/dkz007 sideral 111592 ART-2019-111592 eng Requena, S. Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain. 2019 Access copy available to the general public Unrestricted Background: HIV-2 is a neglected virus despite estimates of 1–2 million people being infected worldwide. The virus is naturally resistant to some antiretrovirals used to treat HIV-1 and therapeutic options are limited for patients with HIV-2. Methods: In this retrospective observational study, we analysed all HIV-2-infected individuals treated with inte- grase strand transfer inhibitors (INSTIs) recorded in the Spanish HIV-2 cohort. Demographics, treatment modal- ities, laboratory values, quantitative HIV-2 RNA and CD4 counts as well as drug resistance were analysed. Results: From a total of 354 HIV-2-infected patients recruited by the Spanish HIV-2 cohort as of December 2017, INSTIs had been given to 44, in 18 as first-line therapy and in 26 after failing other antiretroviral regimens. After a median follow-up of 13 months of INSTI-based therapy, undetectable viraemia for HIV-2 was achieved in 89% of treatment-naive and in 65.4% of treatment-experienced patients. In parallel, CD4 gains were 82 and 126cells/mm3, respectively. Treatment failure occurred in 15 patients, 2 being treatment-naive and 13 treatment-experienced. INSTI resistance changes were recognized in 12 patients: N155H (5), Q148H/R (3), Y143C/G (3) and R263K (1). Conclusions: Combinations based on INSTIs are effective and safe treatment options for HIV-2-infected individ- uals. However, resistance mutations to INSTIs are selected frequently in failing patients, reducing the already limited treatment options. info:eu-repo/grantAgreement/EC/FP7/223131/EU/Collaborative HIV and Anti-HIV Drug Resistance Network/CHAIN info:eu-repo/semantics/openAccess All rights reserved http://www.europeana.eu/rights/rr-f/ 5.439 2019 2.23 2019 INFECTIOUS DISEASES 10 / 93 = 0.108 2019 Q1 T1 Infectious Diseases 2019 Q1 PHARMACOLOGY & PHARMACY 22 / 270 = 0.081 2019 Q1 T1 Pharmacology (medical) 2019 Q1 MICROBIOLOGY 24 / 134 = 0.179 2019 Q1 T1 Pharmacology 2019 Q1 Microbiology (medical) 2019 Q1 info:eu-repo/semantics/article info:eu-repo/semantics/acceptedVersion Lozano, AB. Caballero, E. García, F. Nieto, MC. Téllez, R. Fernández, JM. Trigo, M. Rodríguez-Avial, I. Martín-Carbonero, L. Miralles, P. Soriano, V. de, Mendoza, C. HIV-2 Spanish Study Group Rodríguez, C. Vera, M. Del, Romero, J. Marcaida, G. Ocete, MD. Caballero, E. (orcid)0000-0001-5134-1006 Aguilera, A. Universidad de Zaragoza BENITO, R. de, Lejarazu, RO. Rojo, S. Eirós, JM. Ramos, C. García, J. Paz, I. Trigo, M. Diz, J. García-Campello, M. Rodríguez-Iglesias, M. Hernández-Betancor, A. Martín, AM. Ramos, JM. Gimeno, A. Sánchez, V. Gómez-Hernando, C. Cilla, G. Pérez-Trallero, E. Fernández-Pereira, L. Niubó, J. Hernández, M. López-Lirola, AM. Gómez-Sirvent, JL. Force, L. Cabrera, J. Pérez, S. Morano, L. Raya, C. González-Praetorius, A. Cifuentes, C. Peñaranda, M. Nieto, MC. Montejo, JM. Roc, L. Viciana, I. Lozano, AB. Fernández-Fuertes, E. Fernández, JM. García-Bermejo, I. Gaspar, G. Téllez, R. Górgolas, M. Miralles, P. Pérez, L. Valeiro, M. Aldamiz, T. Margall, N. Suárez, A. Rodríguez-Avial, I. Requena, S. Benítez-Gutiérrez, L. Cuervas-Mons, V. de, Mendoza, C. Barreiro, P. Soriano, V. 1008 630 Universidad de Zaragoza Dpto. Microb.Med.Pr.,Sal.Públ. Área Microbiología 74, 5 (2019), 1357-1372 J. antimicrob. chemother. The Journal of antimicrobial chemotherapy 1460-2091 121883 http://zaguan.unizar.es/record/87679/files/texto_completo.pdf Postprint 52269 http://zaguan.unizar.es/record/87679/files/texto_completo.jpg?subformat=icon icon Postprint oai:zaguan.unizar.es:87679 articulos driver 2020-07-16-08:40:17 ARTICLE